Atossa Therapeutics Inc ATOS
News
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
Stocks to Watch: Atossa Therapeutics, Union Pacific

